U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed?
Our U.S. Stem Cell Clinic will perform outpatient procedures using a process in which we isolate a patient #39;s own stem cells from either their own adipose fat tissue or bone marrow. Approximately...
By: U.S. Stem Cell Clinic
See the article here:
U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video
U.S. Stem Cell Clinic: What is Stem Cell Therapy?
What is Stem Cell Therapy? Stem cell therapy attempts to harness the body #39;s own healing potential by isolating stem cells from one location of the body (fat tissue or bone marrow) and relocating...
By: U.S. Stem Cell Clinic
Read the original post:
U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video
The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL
The New Botox: Stem Cell Therapy Cream Reviews http://GoAgelessNow.com The New Botox: Stem Cell Therapy Cream Reviews Stem cell therapy is the use of stem cells to treat or prevent a disease.
By: Jamal Spikes
The rest is here:
The New Botox: Stem Cell Therapy Cream Reviews- Wellington Anti Aging Centre Loxahatchee FL - Video
Chapter 2 Part 7 Glial cells and neural stem cells default
By: Loretta Sandoval
Read the original:
Chapter 2 Part 7 Glial cells and neural stem cells default - Video
Stem Cells For Paralysis
According to the Christopher and Dana Reeve foundation, nearly one in 50 people According to the Christopher and Dana Reeve foundation, nearly one in 50 people are living with paralysis. Until...
By: NewsChannel 5
Continue reading here:
Stem Cells For Paralysis - Video
U.S. Stem Cell Clinic: When should I expect to see results?
It is important to note that we are treating patients with their own adult stem cells, therefore each treatment and response is unique to that patient. No guarantee can be made of what results...
By: U.S. Stem Cell Clinic
Here is the original post:
U.S. Stem Cell Clinic: When should I expect to see results? - Video
Top Stem Cell Technology Companies 2015-2025 Report
Stem cells, an expanding market with vast potential explore developments and commercial prospects What does the future hold for that cellular technology? What progress and sales are possible?...
By: visiongain
See the article here:
Top Stem Cell Technology Companies 2015-2025 Report - Video
Asterias Biotherapeutics
Pedro Lichtinger, President CEO (NYSEMKT: AST) Headquarters: Menlo Park, CA Asterias develops products based on its core technology platforms of pluripotent stem cells and allogeneic dendritic.
By: Alliance for Regenerative Medicine
Read the original post:
Asterias Biotherapeutics - Video
What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey
http://www.Trinity-Spine.com -727-372-9922 what is Stem Cell Therapy for back pain? Watch this video to see how Stem Cell Therapy can immediately help your chronic neck and back pain. Visit our website ...
By: Anderson Flanders
Go here to see the original:
What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video
0dKXZsceBerY 1
This is a short explanation of how the Stem Cell / PRP Joint Regeneration works. - offered by Utah Stem Cells.
By: Utah Stem Cells Clinic
Read the original:
0dKXZsceBerY 1 - Video
Understanding Stem Cells used in Jeunesse Y.E.S Youth Enhancing System Episode 7
Have you heard about telomeres? Not really? Telomeres are the end of the chromosomes, they are here to protect our DNA, there are also made of DNA, but the sequences which are forming 0:43...
By: LIVING WELL HEALTH NETWORK
Here is the original post:
Understanding Stem Cells used in Jeunesse Y.E.S Youth Enhancing System Episode 7 - Video
Back Pain Stem Cell Therapy Doctors Tampa
http://Trinity-Spine.com (727) 372-9922 Stem Cell Therapy Doctor Reviews Everyone was so nice and helpful. They calmed my nerves about having to get this done, and even had really late hours...
By: Anderson Flanders
Read the rest here:
Back Pain Stem Cell Therapy Doctors Tampa - Video
(MENAFN - ProactiveInvestors)
Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis.
The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015.
Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor.
The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said.
This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product.
One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue.
Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue.
Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types.
Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC).
Go here to see the original:
Regeneus hits key stem cell manufacturing milestone
Copy of 0dKXZsceBerY 1
Utah Stem Cells offers a variety of services using Stem Cells and Platelet Rich Plasma. Our Stem Cell Joint Regeneration has proven very effective to our patients, and it #39;s the best alternative...
By: Bill Cimikoski
Read the original:
Copy of 0dKXZsceBerY 1 - Video
PHILADELPHIA -- The American Association for Cancer Research (AACR) is honoring Owen N. Witte, MD, founding director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research and distinguished professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles, with the 55th annual AACR G.H.A. Clowes Memorial Award at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.
Witte, who is also a Howard Hughes Medical Institute investigator and an elected fellow of the AACR Academy, is being recognized for his many contributions to the understanding of human leukemias, immune disorders, and epithelial cancer stem cells. Witte's work, which contributed to the development of several approved targeted therapies, has transformed the lives of patients with Philadelphia chromosome-positive leukemias and B-cell malignancies. He will present his lecture, "Finding Therapeutic Targets for Aggressive Prostate Cancer," Monday, April 20, 5:30 p.m. ET, in the Grand Ballroom of the Pennsylvania Convention Center.
The AACR and Eli Lilly and Company established the G.H.A. Clowes Memorial Award in 1961 to honor Dr. G.H.A. Clowes, a founding member of the AACR and research director at Eli Lilly. This award recognizes an individual with outstanding recent accomplishments in basic cancer research.
Witte's innovative work helped revolutionize modern cancer treatment by defining tyrosine kinases as crucial drug targets in human disease. Most notably, he pinpointed the molecular consequences of the Philadelphia (Ph) chromosome abnormality present in chronic myelogenous leukemia (CML) and related types of leukemia and defined the tyrosine kinase activity of the ABL gene product. These findings played a crucial role in the subsequent development of ABL kinase-targeted therapies, including imatinib (Gleevec), which remains the front-line treatment for Ph-positive CML.
In addition to his research involving ABL, Witte also co-discovered Bruton agammaglobulinemia tyrosine kinase (BTK). This particular kinase is essential for B-cell maturation and when mutated, results in the onset of the immunodeficiency disease, X-linked agammagloblulinemia. Recent studies involving this protein have resulted in the U.S. Food and Drug Administration approval of ibrutinib (Imbruvica), a selective BTK inhibitor, for the treatment of chronic lymphocytic leukemia mantle cell lymphoma, and Waldenstrm macroglobulinemia.
More recently, Witte's work has focused on defining the epithelial stem cell populations that contribute to prostate cancer. He is currently using mass spectrometry approaches to identify kinases that could be potential therapeutic targets for human prostate cancer.
"Much progress has been made in the area of personalized cancer medicine due to the dedication of scientists and physicians around the world, many of whom I've had the pleasure of working with through the AACR's innovative initiatives," said Witte. "But much more work is needed as we seek to understand cancer, which is not a single disease but rather many diseases that develop differently. I thank the AACR for their leadership in this effort and am honored to receive the Clowes Memorial Award."
An active AACR member, Witte has served on the AACR board of directors and several grant review committees. He is a past recipient of the AACR-Richard and Hinda Rosenthal Award and a co-leader of the Stand Up to Cancer Dream Team: Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer. Additionally, he is also serving an appointed term on the President's Cancer Panel.
Witte has been recognized throughout his career with numerous honors. He has received the Nakahara Memorial Lecture Prize, the Cotlove Lectureship from the Academy of Clinical Laboratory Physicians and Scientists, the de Villiers International Achievement Award from the Leukemia and Lymphoma Society, the Warren Alpert Prize, and is elected member of the Institute of Medicine, National Academy of Sciences, and fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.
Witte received his medical degree from Stanford University School of Medicine in California, and was a postdoctoral fellow at the Center for Cancer Research at the Massachusetts Institute of Technology in Cambridge. He joined the UCLA faculty in 1980.
The rest is here:
Dr. Owen Witte recognized with AACR G.H.A. Clowes Memorial Award
Beverly Hills, California (PRWEB) April 07, 2015
Dr. Raj, the top Orthopedic Surgeon in Beverly Hills and Los Angeles, is now offering stem cell therapy to heal chronic tendonitis. The treatment works exceptionally well for those suffering from tendonitis of the rotator cuff, achilles, elbow and knee. For more information and scheduling, call (310) 247-0466.
As a pioneer in regenerative medicine, Dr. Raj has been helping patients with degenerative arthritis achieve relief and avoid joint replacements for years with stem cell procedures. By adding the procedures for tendonitis, Dr. Raj is now helping patients avoid potentially risky surgeries and get back to being more active for soft tissue related pain.
"Surgery for tendonitis is often not 100% successful for patients, and the rehabilitation period may take six months," states Dr. Raj. "With the stem cell therapy, pain relief is quick and athletes get back to sports faster!"
Regenerative medicine for tennis elbow has been shown in research studies to be effective at relief and helping avoid surgery. A 2013 study out of South Florida showed that 28 out of 30 patients with chronic tennis elbow avoided surgery and got back to being very active.
For several years in a row, Dr. Raj has been named the top orthopedic doctor in Los Angeles and Beverly Hills. He is an ABC News Medical Correspondent as well as a WebMD Medical Expert.
Hundreds of patients have benefited from stem cell procedures with Dr. Raj at Beverly Hills Orthopedic Institute. They come from all over Southern California, along with throughout the country. Call (310) 247-0466 for scheduling stem cell therapy with an orthopedic surgeon Beverly Hills trusts and respects.
Here is the original post:
Dr. Raj at Beverly Hills Orthopedic Institute Now Offering Stem Cell Therapy to Heal Chronic Tendonitis
Miami, FL (PRWEB) April 06, 2015
Regenestem Network, a subsidiary of the Global Stem Cells Group, has announced plans to attend the 23rd Annual World Congress on Anti-Aging Medicine (a4m) at the Diplomat Resort and Spa in Hollywood, Fla. Hosted by the American Academy of Anti-aging Medicine, the conference will be attended by physicians and medical practitioners from around the world.
Regenestem Network plans to showcase its upcoming stem cell training course, Adipose Derived and Bone Marrow Stem Cell course, with classes scheduled to be held May 9-10 and June 15-16, 2015 in Miami. The intensive, two-day course covers the latest technology and procedures in adipose and bone marrow stem cell therapies. Participants learn skills that can be used in their own practice and for career advancement.
A4m Conference Keynote speakers include Daniel G. Amen, MD, David Perlmutter, MD, FACN, ABIHM, and Gary Small, MD. All three will focus on disease prevention and optimized health through a proactive treatment approach. These world-renown speakers are scheduled to deliver insightful presentations, the latest research and breakthrough therapies in anti-aging medicine.
To learn more about the 23rd Annual World Congress on Anti-Aging Medicine, visit the a4m website. For more information on the Regenestem Network, visit the website at regenestemnetwork.com. For more information on the stem cell training classes, visit the http://www.stemcelltraining.net website, email bnovas(at)regenestem(dot)com, or call 849.943.2988.
About Regenestem Network:
Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.
Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
About the Global Stem Cell Group:
Read this article:
Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015
Autistic Minority International - CRPD side event - 2 April 2015
Side event on occasion of the UN #39;s World Autism Awareness Day 2015 "Medical Experimentation on Autistic Children: Fake Cures and Global Stem Cell Tourism", organized by Autistic Minority ...
By: Erich Kofmel
Read this article:
Autistic Minority International - CRPD side event - 2 April 2015 - Video
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D.
Bill describes his result one year after bone marrow stem cell therapy by Dr. Harry Adelson for low back pain caused by a degenerated and herniated lumbar disc.
By: Harry Adelson, N.D.
See the original post here:
Degenerated/herniated lumbar discs 1 year after stem cell therapy by Harry Adelson, N.D. - Video
Life-changing results: Sandra Sharman is a private stem cell patient. Photo: Meredith O'Shea
Last week, Suzie Palmer, 44, travelled from her home in NSW to the Gold Coast for her second round of stem cell treatments for multiple sclerosis. OnTuesday morning,the wheelchair-bound poet underwent liposuction.
By 2.30pm, stem cells had been partially separated from her abdominal fat, suspended in plasma, and injected intravenously. Her doctor, Soraya Felix, is a cosmetic surgeon and molecular biologist with a sideline in regenerative medicine.
Palmer, a relentlessly upbeat and positive person, says the treatments have helped her cope better with heat, improved her mobility and flexibility and otherwise made her "feel like a normal human being". She has, she says, managed a few steps with a walker, still a long way from "running about, which is my dream".
Poster girl: Suzie Palmer is undergoing stem cell therapy for MS. Photo: Edwina Pickles
The rapidly growing stem cell industry is aglow with similarly positive testimonials, notably on behalf of practitioners who offer little documented scientific evidence of their success.
Advertisement
Suzie Palmer is literally the poster girl for stem cell tourism within Australia. You can find her smiling sweetly, along with Dr Felix, on the Facebook page of a group called the Adult Stem Cell Foundation. She is one of an unknown number of unwell Australians pinning their hopes on an unregulated industry that is now under review by the Therapeutic Goods Administration.
The TGA public consultation, which closed earlier this month, was prompted by long-standing concerns raised by Stem Cells Australia that a loophole in the regulations has allowed dozens of doctors across Australia to provide experimental treatments without the ethics committee oversight that registered clinical trials are subject to. These treatments invariably cost $10,000 and up. The loophole is this: while the use of donor stem cells in therapies is tightly regulated, the use of a patient's own stem cells is not.
Professor Martin Pera is the program leader of Stem Cells Australia, which is administered by the University of Melbourne and includes scientists from Monash University, the Walter and Eliza Hall Institute for Medical Research, the Florey Institute and the CSIRO, among others. They are engaged in a seven-year Australian Research Council project to answer the big questions about stem cells and the potential for reliable therapies.
See the original post:
Is a loophole in stem cell law helping new therapy to thrive, or allowing dubious science?